Novartis

Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent | 10/11/2019

James Love Health Law Policy , Intellectual Property , James Love , Research Funding By James Love This is a story about U.S. patent number 6,958,335 , and how it took more than 18 years for Novartis to acknowledge National Institutes of Health (NIH) funding in a key patent for Gleevec, allowing Novartis to shape the narrative regarding its role in the development of Gleevec, and also to avoid demands that Novartis make the …

Dedicated app measures outcomes of presbyopia eye drops | 10/10/2019

An app that is closely related to the development of UNR844 presbyopia-correcting ophthalmic solution from Novartis effectively measures vision changes at home, monitoring the effects and potentially warning the patient when it is time to repeat the treatment. “Within our clinical studies, vision is measured in the clinic with the traditional tests, then with the app, and then the app is used at home. One of our goals is …

Follow Novartis:    

Is Novartis AG (VTX:NOVN) Trading At A 38% Discount? | Yahoo News | 10/10/2019

Is Novartis AG (VTX:NOVN) Trading At A 38% Discount? Simply Wall St Reblog Does the October share price for Novartis AG ( VTX:NOVN ) reflect what it’s really worth? Today, we will estimate the stock’s intrinsic value by projecting its future cash flows and then discounting them to today’s value. This is done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple …

Novartis has its blockbuster Beovu OK, but its ‘hot mess’ label leaves something to be desired: analysts | FiercePharma | 10/10/2019

… many patients discontinue treatment, Novartis’ global head of medical affairs Marcia Kayath previously told FiercePharma. Beovu also carries a 4% risk of intraocular inflammation, the FDA label says, compared with 1% for Eylea. RELATED: Novartis takes on Regeneron, Roche blockbusters with Beovu approval The expert who spoke with Porges predicted that doctors will start 10% to 15% of wet AMD patients on the drug within the next six months. Further …

Department of Health partners with Plug and Play to support healthcare startups | PR Newswire | 10/9/2019

ABU DHABI, United Arab Emirates , Oct. Department of Health Abu Dhabi has announced its partnership with Plug and Play , the largest global innovation platform headquartered in Silicon Valley, and Abu Dhabi Global Market (ADGM), the award-winning international financial centre in Abu Dhabi . This is the first established Health startup accelerator in the MENA region. According to the partnership, DOH aims to support healthcare startups by connecting them to networks …

Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target | PR Newswire | 10/9/2019

TOKYO and LONDON , Oct. 9, Sosei Group Corporation (“the Company”; TSE: 4565) announces that it has been notified by its partner Genentech, a member of the Roche Group, of its desire to nominate a new G protein-coupled receptor (GPCR) disease target, which has triggered a US$3 million payment to Sosei Heptares. Sosei Heptares and Genentech entered into their collaboration and license agreement in July 2019 to combine the …

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019 | PR Newswire | 10/9/2019

… Inc Aclaris Therapeutics Inc Alvotech ehf AstraZeneca Plc Celgene Corp ChemoCentryx Inc CSL Ltd Foamix Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd Immunwork Inc Incyte Corp InflaRx NV Innovation Pharmaceuticals Inc InSight Biopharmaceuticals Ltd Johnson & Johnson Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles ABBV-3373 - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar …

ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute | PR Newswire | 10/9/2019

… lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on human T cells and …

Planbox Makes Waves With Imagine Innovation Management User Conference | PR Newswire | 10/9/2019

FORT LAUDERDALE, Fla. Planbox, a leading provider of cloud-based AI-Powered Agile Innovation Management solutions, brought together thought leaders and practitioners from some of the world’s leading organizations to share their expert guidance, winning strategies, and inspirational innovation success stories for the 2019 Planbox Imagine innovation management user conference in Fort Lauderdale, Florida . Continue Reading Planbox “Many thanks to the entire Planbox team (those present as well as those …

The Global CAR T-Cell Therapy market is expected to grow at a CAGR of 56.2% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Bellicum Pharmaceuticals, Inc., Pfizer, Inc, Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells …

Controlled Release Drug Delivery Market Expected to Reach 14% CAGR till 2023 – Says MRFR | 10/9/2019

… and small market players which operate in this market all over the globe. Corium International Inc.(US), Collegium Pharmaceutical(US), Alza Corporation (Johnson & Johnson)(US), Pfizer Inc.(US), AstraZeneca (US),Biogen (US), GlaxoSmithKline (UK), Novartis (UK), Depomed, Inc. (US), Allergan (‎Ireland), Coating Place, Inc.(US), SKY Pharmaceuticals Pvt. Ltd.(China), and others. Get Exclusive Sample Copy of “Controlled Release Drug Delivery Market” Report @ https://www.marketresearchfuture.com/sample_request/6794 Controlled Release …

New Novartis Drug Tabbed as Blockbuster | Yahoo News | 10/9/2019

… help differentiate it in the market. Sales of Eylea were more than $4 billion in 2018. Meanwhile, Roche has a next-generation wet AMD candidate called Faricimab, but it’s still in phase 3 testing. Novartis is counting on Beovu to bolster its collection of ophthalmology products, which now includes 70 drugs used to treat a wide range of conditions, according to a FiercePharma article. The franchise definitely could use the …

Of the upcoming new approaches, what do you expect to be the best for the treatment of early presbyopia? | 10/9/2019

… solid understanding of surgical options, which also have a bright future as our population ages. William B. Trattler, MD, is OSN Technology Section Editor. Disclosure: Trattler reports he is a consultant to Allergan and Novartis and has a financial interest in Visionary Ventures, which has a financial interest in Orasis. Scleral microporation is effective, not invasive Magda Rau I have worked for about 2 years now on laser scleral microporation …

The Global Generic Drugs market is expected to reach $738.56 billion by 2026 growing at a CAGR of 12.6% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Cipla, Abbott Laboratories, Novartis International AG, Nichi-Iko Pharmaceutical, Mylan NV, Valeant, Hospira (Pfizer Inc.), Dr. Reddy’s, Sresenius Kabi Ag, Baxter International Inc., Actavis Pharmaceuticals, and Eli Lilly and Company. Hyderabad, India - October 9, 2019 /MarketersMedia/ — These drugs are cheaper and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations in various countries …

Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept | 10/9/2019

… agents than other anti-VEGFs 2 . By inhibiting VEGF, BEOVU suppresses the growth of abnormal blood vessels and the potential for fluid leakage into the retina 2 . “The approval of BEOVU delivers on the Novartis commitment to reimagining treatments for patients suffering from serious visual impairment,” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “The product labels of existing treatments state that they are not as effective when dosed every 12 …

Global The Animal Health market is expected to reach $80.39 billion by 2026 growing at a CAGR of 7.6% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Zoetis Inc., Bayer AG, Nutreco N.V., Novartis, Merck Animal Health, Thermo Fisher Scientific, Elanco, Boehringer Ingelheim GmbH, Virbac, Heska, Vetiquinol S.A., Biogenesis Bago, Ceva Sante Animale, Neogen, Eli Lilly, and Merial. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Animal health is a branch of veterinary science deals with treatment and monitoring of animal disease. It plays an important role in the economy and safety of the …

Novartis AG (NYSE:NVS) Holdings Trimmed by Scout Investments Inc. | 10/9/2019

Scout Investments Inc. trimmed its position in shares of Novartis AG (NYSE:NVS) by 18.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 141,513 shares of the company’s stock after selling 31,074 shares during the period. Scout Investments Inc.’s holdings in Novartis were worth $12,297,000 at the end of the most recent reporting period. A number of …

Brolucizumab wins FDA approval, introducing extended dosing for wet AMD | 10/9/2019

… they are not as effective when dosed every 12 weeks. Beovu is the first to offer less frequent dosing in the first year of therapy while maintaining its effectiveness,” says Marie-France Tschudin, President, Novartis Pharmaceuticals. “This gives more time for wet AMD patients to focus on what’s important in their lives.” In both clinical trials, about 30% of patients gained at least 15 letters by year 1 . Compared with …

With new CBD plant open, Mile High Labs wants to set the industry standard | 10/9/2019

… CBD universe.” Sponsored Content Mile High announced that it would buy the plant, a pharmaceutical plant formerly owned by Sandoz Inc. , for about $18.8 million in June. Sandoz, a subsidiary of Swiss pharma giant Novartis AG, began shutting down operations there in early 2018 and laid off about 450 workers over several months. In an interview after the event with BizWest, Mueller said the plant currently has about 100 employees …

Parliament approves probe into ex SYRIZA minister over Novartis handling | 10/9/2019

The Greek Parliament approved the proposal of New Democracy to set up a special investigation committee to probe former Alternate Justice Minister Dimitris Papangelopoulos (SYRIZA). The committee will probe into Papangelopoulos’ possible involvement in crimes related with the Novartis case. The former SYRIZA minister has been accused of interfering and manipulating into Novartis probe. “Reading the evidence in the case file shows there are clear indications of illegitimate intervention by …

Food and Drug Administration

NVS LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG NVS | Financial Buzz | 10/9/2019

NEW YORK, Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public. On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) issued a statement revealing that data submitted in the Company’s biologics license application (“BLA”) for its gene …

NVS LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS - GuruFocus.com | 10/9/2019

NEW YORK, Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public. On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) issued a statement revealing that data submitted in the Company’s biologics license application (“BLA”) for its gene therapy …

Biotech

The Global CAR T-Cell Therapy market is expected to grow at a CAGR of 56.2% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Bellicum Pharmaceuticals, Inc., Pfizer, Inc, Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells …

Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO | FierceBiotech | 10/8/2019

After poaching an ex-Merck exec to run its R&D, Chinese biotech Ascletis has raided another U.S. Big Pharma for its new chief scientific officer. The company has poached Handan He , Ph.D., a 22-year veteran of Swiss major Novartis, as its new CSO. She was most recently the global head of computational, biopharmaceutics and translational PK/PD at Novartis where she managed scientific teams across the U.S. and …

Gene Therapy

Global Gene Therapy Industry | The Wapakoneta Daily News | 10/8/2019

New York, Oct. 08, 2019 (GLOBE NEWSWIRE) – Reportlinker.com announces the release of the report “Global Gene Therapy Industry” - https://www.reportlinker.com/p05817594/?utm_source=GNW - Representing the developed world, the United States will maintain a 30 … Cells Institute PJSC (HSCI); Juno Therapeutics, Inc.; Lonza Group Ltd.; Novartis International AG; Novasep Holding SAS; Orchard Therapeutics Ltd.; Oxford Biomedica plc; REGENXBIO, Inc.; Sanofi Genzyme; Shanghai Sunway Biotech Co., Ltd.; Shenzhen SiBiono GeneTech Co …

Early data for Novartis gene therapy show improvements for older spinal muscular atrophy patients | MedCity News | 10/7/2019

BioPharma Early data for Novartis gene therapy show improvements for older spinal muscular atrophy patients Interim Phase I/II data for Zolgensma showed improvements in children aged 2 to less than 5 with spinal muscular atrophy. The therapy received FDA approval in May for infants younger than 2 …

Big Pharma

Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO | FierceBiotech | 10/8/2019

After poaching an ex-Merck exec to run its R&D, Chinese biotech Ascletis has raided another U.S. Big Pharma for its new chief scientific officer. The company has poached Handan He , Ph.D., a 22-year veteran of Swiss major Novartis, as its new CSO. She was most recently the global head of computational, biopharmaceutics and translational PK/PD at Novartis where she managed scientific teams across the U.S. and …

Clinical Data

Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept | PR Newswire | 10/8/2019

EAST HANOVER, N.J. , Oct. 8, Novartis today announced that the U.S. Food and Drug Administration (FDA) approved BEOVU ® (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD … development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and …

Clinical Data Release Points to Veyonda® Boosting the Effectiveness of Radiotherapy in Prostate Cancer | 10/3/2019

Australian clinical-stage drug development company, Noxopharm Limited (ASX: NOX) , has provided commentary on clinical data to be released to a cancer conference in November. Noxopharm believes that the data adds to the growing body … do something about this is the large Swiss pharma company, Novartis. It paid US$6 billion in 2018 for a technology that it hopes will bring hope for men with late-stage prostate cancer. It …

American Society of Clinical Oncology

Novartis Investigational Lung Cancer Therapy Capmatinib (INC280) Granted FDA Breakthrough Therapy Designation for Patients with MET-Mutated Advanced Non-Small Cell Lung Cancer | 9/6/2019

… mutated non-small cell lung cancer (NSCLC),” said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis. Recent research concludes that the cMET gene is an oncogenic driver[1],[2], and … GEOMETRY mono-1 study presented at the 2019 meeting of American Society of Clinical Oncology. Please click link for complete study results [http://bit.ly/2L7L3ta] Capmatinib (INC280) is an investigational, oral, highly potent and selective …

The Corporate Reputation of Pharma in 2018: Cancer Patient Perspective Survey - ResearchAndMarkets.com | Business Wire | 8/14/2019

… industry’s drop in corporate reputation among rare-cancer patient groups may seem surprising, given a January 2019 announcement by the American Society of Clinical Oncology (ASCO) that research to treat rare cancers comprises the Advance … 2018 (as reported by all respondent cancer patient groups): Janssen, Novartis, Pfizer, and Roche/Genentech. Janssen was ranked overall 1st out of 36 companies for corporate reputation in 2018 by the 139 respondent cancer patient …

Biosimilars

AbbVie Stock: Is It A Buy Right Now? Here’s What Earnings, ABBV Stock Chart Show | Investor’s Business Daily | 10/3/2019

… to $2.26 per share, but growth decelerated for the third consecutive quarter. The sales decline follows European approvals of Humira biosimilars . Humira is an arthritis, psoriasis and Crohn’s disease treatment. AbbVie is heavily reliant on … to acquire something to diversify itself from Humira. Amgen ( AMGN ), Novartis ( NVS ), Mylan ( MYL ) and Biogen ( BIIB ) with partner Samsung have launched Humira biosimilars in Europe. Deals with AbbVie will allow them to launch in …

Biogen Stock: Is It A Buy Right Now? Here’s What Earnings, BIIB Stock Chart Say | Investor’s Business Daily | 10/1/2019

… treatment. Biogen is testing a higher dose of its spinal muscular atrophy treatment, Spinraza, as the biotech faces competition from Novartis ‘ ( NVS ) gene therapy , Zolgensma. So, as Biogen rebuilds in the wake of its high … notable spinal muscular atrophy treatment called Spinraza, as well as biosimilars of key drugs from Amgen ( AMGN ), AbbVie ( ABBV ) and Johnson & Johnson ( JNJ ). Notably, the biotech company has eight quarters of sales and earnings growth …

Medicare

Metavivor Announces the Stage IV Stampede and Launch of the 2019-2020 Advocacy Agenda | PRWeb | 10/8/2019

… the Breast of Us to help share the importance of advocating for addition Corporate sponsors of the advocacy plan include Novartis, Pfizer, Seattle Genetics and Eisai. The coalition of organizations is focused on achieving the … innovative therapies, and end the waiting period for disability and Medicare benefits for individuals facing terminal illness. 5. Support efforts to ensure new treatment options for metastatic cancer patients, in all forms, are available and …

September 2019 Briefing - Pharmacy | 10/1/2019

Novartis, the maker of a generic form of Zantac, said Wednesday it will cease distribution of the medicine after investigations suggested that generic and branded versions contain a known carcinogen. More Information: FDA House Speaker Unveils Plan to Lower Drug Costs THURSDAY, Sept. 19, House Speaker Nancy Pelosi has revealed a plan to lower the cost of medications for people on Medicare and those with private insurance. AP News Article …

AMA

Former Novartis CEO and Eli Lilly’s Drug Development Leader are Featured Keynote Speakers at Veeva R&D Summit | Business Wire | 8/22/2019

PLEASANTON, Calif.–(BUSINESS WIRE)–Aug 22, 2019– Veeva Systems (NYSE:VEEV) today announced that Joe Jimenez, former CEO of Novartis, and Rob Metcalf, vice president of medicines development at Eli Lilly and Company, are featured … Pharma. 2019 Veeva R&D Summit platinum sponsors include Accenture, Amazon Web Services, Kinapse, NNIT, PWC, and Valiance. Gold sponsors include C3i Solutions, CGI, Daelight Solutions, Deloitte, Eagle Productivity, FME, GenPact, Ideagen PLC, LMK Clinical …

AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer | Business Wire | 8/16/2019

Novartis Institutes of Biomedical Research (NIBR) in Cambridge MA, where she partnered with executive leaders and their scientific research teams across seven sites in the US, Asia and Europe, in co-creating organizational vision, and developing operations to achieve increased innovation, effectiveness and collaboration across multiple disease portfolios. Previously at Biogen Idec, and other major companies including Amazon and Microsoft, Ms. Verdin is a global human resources leader with broad …

CAR-T

CAR-T Therapies Market (2nd Edition), 2019-2030 | PR Newswire | 10/1/2019

CAR-T cell therapies are based on the principle of harnessing the innate potential of the immune system to selectively target and destroy diseased cells. Encouraging clinical results reported across several completed and ongoing trials, coupled to lucrative financing, have inspired many biopharmaceutical developers and academic research groups to focus their efforts on this relatively novel class of cell-based immunotherapies. With two approved products, namely KYMRIAH® (Novartis) and YESCARTA …

CAR-T Therapies Market, 2030 - Current Market Landscape and the Future Potential - ResearchAndMarkets.com | Business & Finance | manchestertimes.com | Business Wire | 9/30/2019

The “CAR-T Therapies Market (2nd Edition), 2019-2030” report has been added to ResearchAndMarkets.com ‘s offering The CAR-T Therapies Market, 2019-2030 (2nd edition) report features an extensive study of the current market landscape and … of cell-based immunotherapies. With two approved products, namely KYMRIAH (Novartis) and YESCARTA (Gilead Sciences), CAR-T cell therapies are presently considered among the most promising anticancer therapeutics available, with potential applications in treating other …

Pfizer

Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target | PR Newswire | 10/9/2019

Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK . “Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit https://www.soseiheptares.com/ LinkedIn: @soseiheptaresco Twitter: @soseiheptaresco YouTube: @soseiheptaresco Enquiries: Sosei Heptares Investor Relations and Corporate Communications Shinichiro Nishishita, Mai Kurokawa +81-(0)-3-5210-3399 IR …

The Global CAR T-Cell Therapy market is expected to grow at a CAGR of 56.2% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Bellicum Pharmaceuticals, Inc., Pfizer, Inc, Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells …

Merck

ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute | PR Newswire | 10/9/2019

Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients. The Phase 1 dose-escalation study conducted with cancer patients receiving immunotherapy treatments has demonstrated safety, established the …

Global The Animal Health market is expected to reach $80.39 billion by 2026 growing at a CAGR of 7.6% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Zoetis Inc., Bayer AG, Nutreco N.V., Novartis, Merck Animal Health, Thermo Fisher Scientific, Elanco, Boehringer Ingelheim GmbH, Virbac, Heska, Vetiquinol S.A., Biogenesis Bago, Ceva Sante Animale, Neogen, Eli Lilly, and Merial. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Animal health is a branch of veterinary science deals with treatment and monitoring of animal disease. It plays an important role in the economy and safety of the …

GlaxoSmithKline

Controlled Release Drug Delivery Market Expected to Reach 14% CAGR till 2023 – Says MRFR | 10/9/2019

GlaxoSmithKline (UK), Novartis (UK), Depomed, Inc. (US), Allergan (‎Ireland), Coating Place, Inc.(US), SKY Pharmaceuticals Pvt. Ltd.(China), and others. Get Exclusive Sample Copy of “Controlled Release Drug Delivery Market” Report @ https://www.marketresearchfuture.com/sample_request/6794 Controlled Release Drug Delivery Market - Scenario Controlled release drug delivery involves releasing drug through drug-encapsulating devices at controlled rates for long periods to facilitate optimal use of drugs and tailoring of drug release …

Global Gene Therapy Industry | The Wapakoneta Daily News | 10/8/2019

GlaxoSmithKline PLC; Human Stem Cells Institute PJSC (HSCI); Juno Therapeutics, Inc.; Lonza Group Ltd.; Novartis International AG; Novasep Holding SAS; Orchard Therapeutics Ltd.; Oxford Biomedica plc; REGENXBIO, Inc.; Sanofi Genzyme; Shanghai Sunway Biotech Co., Ltd.; Shenzhen SiBiono GeneTech Co., Ltd.; Shire PLC; Taxus Cardium Pharmaceuticals Group; Transgene SA; Ultragenyx Pharmaceutical, Inc.; uniQure NV; Voyager Therapeutics, Inc. Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE …

Bristol-Myers Squibb

Global Gene Therapy Industry | The Wapakoneta Daily News | 10/8/2019

Bristol-Myers Squibb Company; Celgene Corporation; Cellectis; CELLforCURE; CEVEC Pharmaceuticals GmbH; Chiesi Farmaceutici SpA; CSL Behring; Gensight Biologics S.A.; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Human Stem Cells Institute PJSC (HSCI); Juno Therapeutics, Inc.; Lonza Group Ltd.; Novartis International AG; Novasep Holding SAS; Orchard Therapeutics Ltd.; Oxford Biomedica plc; REGENXBIO, Inc.; Sanofi Genzyme; Shanghai Sunway Biotech Co., Ltd.; Shenzhen SiBiono GeneTech Co., Ltd.; Shire PLC; Taxus Cardium Pharmaceuticals Group; Transgene SA …

Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market | PR Newswire | 10/7/2019

Bristol-Myers Squibb (BMS) • Celgene • Merck & Co., Inc. • Novartis • Pfizer • Roche • Sanofi • Takeda • Teva • Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs. • SWOT Analysis and Porter’s Five Forces analysis of the global rare disease drugs market • Discussion on factors that drive and restrain the global rare disease drugs market as well …

Sandoz

Vectura, Sandoz gets favorable ruling in inhaler packaging case against GSK | 10/4/2019

Reuters) - Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK’s asthma inhaler, Seretide Accuhaler. GSK, with which Vectura …

Vectura, Sandoz win ruling on inhaler packaging case against GSK | News | WIBQ | 10/4/2019

Reuters) - Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK’s asthma inhaler, Seretide Accuhaler. GSK, with which Vectura …

Bristol-Myers

Cardiovascular Drugs: Global Industry Outlook to 2022 Featuring Merck & Co, Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis, and More | Globe Newswire | 9/25/2019

… xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns … Companies Mentioned: Merck & Co, Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis Metrics Covered: Hypertension Prevalence Rate, Number of Enterprises, Number of Employees Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East …

Cardiovascular Drugs: Global Industry Outlook to 2022 Featuring Merck & Co, Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis, and More | Benzinga | 9/25/2019

… xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. The report covers market characteristics, size and growth, segmentation, regional and country … Companies Mentioned: Merck & Co, Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis Metrics Covered: Hypertension Prevalence Rate, Number of Enterprises, Number of Employees Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East …

AbbVie

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019 | PR Newswire | 10/9/2019

AbbVie Inc Aclaris Therapeutics Inc Alvotech ehf AstraZeneca Plc Celgene Corp ChemoCentryx Inc CSL Ltd Foamix Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd Immunwork Inc Incyte Corp InflaRx NV Innovation Pharmaceuticals Inc InSight Biopharmaceuticals Ltd Johnson & Johnson Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles ABBV-3373 - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab …

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report | 10/8/2019

Novartis announces positive results from two Entresto t … September 5, 2019 Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report AbbVie’s enjoying industry-leading sales for Humira these days, but by 2025, the drug will fall down the rankings to the No. 6 spot in best-selling meds, according to a new forecast from GlobalData. Meanwhile, the analysts expect Merck’s Keytruda to continue making strides and reach $22.5 …

Biogen

Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market | PR Newswire | 10/7/2019

… discussion on the leading companies in the rare disease drugs market: • AbbVie • Bristol-Myers Squibb (BMS) • Celgene • Merck & Co., Inc. • Novartis • Pfizer • Roche • Sanofi • Takeda • Teva • Rare disease drugs pipeline analysis covering rare oncology drugs … HealthCare Pharmaceuticals Belrose Pharmaceuticals BerGenBio BioBlast Pharma BioCryst Pharmaceuticals Biodel Biogen BioInvent International BioLineRx BioMarin Pharmaceutical BioNTech Bio-Path Holdings Biotest Pharmaceuticals Blaze Bioscience bluebird bio Blueprint Medicines Boehringer Ingelheim Pharmaceuticals Bristol- Myers Squibb Burzynski …

Novartis’ latest Zolgensma data bode well for use in older patients | FiercePharma | 10/7/2019

by Eric Sagonowsky Oct 7, 2019 11:00am SMA patients ages 2 to 5 who received Novartis’ SMA gene therapy Zolgensma showed significant improvements in motor function, the company says. (Zolgensma) Biogen and Novartis have been battling in spinal muscular atrophy ever since Novartis won approval for its gene therapy Zolgensma, threatening Biogen’s blockbuster Spinraza. Now, Novartis is the latest to tout data for its offering in patients between 2 and …

GSK

Vectura, Sandoz gets favorable ruling in inhaler packaging case against GSK | 10/4/2019

Reuters) - Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK’s asthma inhaler, Seretide Accuhaler. GSK, with which Vectura …

Vectura, Sandoz win ruling on inhaler packaging case against GSK | News | WIBQ | 10/4/2019

Reuters) - Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK’s asthma inhaler, Seretide Accuhaler. GSK, with which Vectura …

Celgene

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019 | PR Newswire | 10/9/2019

Celgene Corp ChemoCentryx Inc CSL Ltd Foamix Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd Immunwork Inc Incyte Corp InflaRx NV Innovation Pharmaceuticals Inc InSight Biopharmaceuticals Ltd Johnson & Johnson Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles ABBV-3373 - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R …

The Global CAR T-Cell Therapy market is expected to grow at a CAGR of 56.2% from 2018 to 2026. | 10/9/2019

The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Bellicum Pharmaceuticals, Inc., Pfizer, Inc, Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech. Hyderabad, India - October 9, 2019 /MarketersMedia/ — Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells …

Goldman Sachs

Novartis (VTX:NOVN) Given a CHF 105 Price Target by Goldman Sachs Group Analysts | 10/8/2019

Goldman Sachs Group set a CHF 105 price target on Novartis (VTX:NOVN) in a report issued on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock. A number of other research analysts have also commented on NOVN. UBS Group set a CHF 90 price target on Novartis and gave the stock a neutral rating in a report on Tuesday, September 10th. Bank of …

Goldman Sachs Group Analysts Give Novartis (VTX:NOVN) a CHF 105 Price Target | 9/22/2019

Goldman Sachs Group set a CHF 105 price objective on Novartis (VTX:NOVN) in a research report sent to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock. NOVN has been the subject of several other research reports. JPMorgan Chase & Co. set a CHF 82 target price on Novartis and gave the company a sell rating in a research note on Monday …

Morgan Stanley

Novartis (NYSE:NVS) Given New $105.00 Price Target at Argus | 8/15/2019

Novartis (NYSE:NVS) Given New $105.00 Price Target at Argus Posted by Elija Maina on Aug 14th, 2019 Novartis (NYSE:NVS) had its price target increased by research analysts at Argus to $105.00 in a … for the company in a report on Wednesday, April 24th. Morgan Stanley cut Novartis from an “equal weight” rating to an “underweight” rating and upped their price target for the stock from $82.50 to $82.52 …

Ionis Pharmaceuticals, Inc. (IONS) CEO Stanley Crooke on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/7/2019

… Piper Jaffray Jim Birchenough - Wells Fargo Chad Messer - Needham & Company Ritu Baral - Cowen & Company Yale Jen - Laidlaw & Company David Lebowitz - Morgan Stanley Jessica Fye - JP Morgan Operator Good morning, and welcome to Ionis Pharmaceuticals Second … medicines based in our technology advanced and $150 million from Novartis for licensing AKCEA-APO(a)-LRx in the first quarter. Our non-GAAP operating expenses in the first-half of this year were $271 …

Jefferies Financial Group

Novartis AG (NYSE:NVS) Given Consensus Rating of “Hold” by Brokerages - Ticker Report | 10/8/2019

Novartis AG (NYSE:NVS) has been assigned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a … for the company. in a report on Friday, July 19th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, August 29th. ValuEngine cut Novartis from a “hold” rating …

Novartis’ (NYSE:NVS) Buy Rating Reaffirmed at Jefferies Financial Group | 9/23/2019

Jefferies Financial Group reaffirmed their buy rating on shares of Novartis (NYSE:NVS) in a research note released on Thursday, August 29th, Borsen Zeitung reports. A number of other research analysts have also recently commented on NVS. Kepler Capital Markets cut Novartis from a buy rating to a hold rating in a research note on Tuesday, July 23rd. Zacks Investment Research downgraded Novartis from a buy rating to a hold …

Biogen Idec

Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR | BMJ | 8/21/2019

Novartis, Biogen Idec, Sanofi Aventis and Merck-Serono; and has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. LvdB serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen, Cytokinetics, Orion and Sarepta. SP, AEV, FD, JV, LP, GL, EP, JHV and RV report no potential conflicts of interest. Patient consent for publication Not required. Provenance and …

AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer | Business Wire | 8/16/2019

Novartis Institutes of Biomedical Research (NIBR) in Cambridge MA, where she partnered with executive leaders and their scientific research teams across seven sites in the US, Asia and Europe, in co-creating organizational vision, and developing operations to achieve increased innovation, effectiveness and collaboration across multiple disease portfolios. Previously at Biogen Idec, and other major companies including Amazon and Microsoft, Ms. Verdin is a global human resources leader with broad …

Advent International

Still on a cash-raising spree, Takeda shops €1.5B European drug sale: report | FiercePharma | 7/18/2019

… its backers Cinven and Bain Capital; Italy’s Recordati and its investor CVC Capital Partners; and Zentiva, which Sanofi sold to Advent International last year. But Takeda could have competition for those bidders: They’re among those … neuroscience. Takeda already sold Shire’s dry eye drug Xiidra to Novartis in a deal potentially worth $5.3 billion, and handed Johnson & Johnson its TachoSil surgical patch. It’s also close to finalizing a buyer for its …

SVB Leerink

Novartis Stock Dips After FDA OKs Eye-Disease Treatment Rival To Eylea | Investor’s Business Daily | 10/8/2019

Novartis ( NVS ) gained Food and Drug Administration approval Tuesday for an eye-disease treatment that could undercut Regeneron Pharmaceuticals ‘ ( REGN ) blockbuster drug Eylea. X Both drugs treat wet age-related macular degeneration, or wet AMD … competing drugs which, Novartis says, should boost patient compliance. But SVB Leerink analyst Geoffrey Porges says Eylea sales could still grow for another year or two. “Beovu’s label shows higher safety liabilities than Eylea, with …

When it comes to cancer drug deals, one hot protein family is raking in billions: report | FiercePharma | 8/21/2019

… pharma M&A—one that has spawned nearly $100 billion in deals since 2010, according to a new analysis from SVB Leerink. Almost 40% of the total value of pharma deals completed in that timeframe … pointed out. The recently developed CDK 4/6 inhibitors—Pfizer’s Ibrance, Novartis’ Kisqali and Lilly’s Verzenio—are similarly priced and labeled, the analysts wrote. Pfizer is leading the class so far due to “a perception of …

BlackRock

Stocks making the biggest moves premarket: BlackRock, Cloudera, Tyson Foods & more | CNBC | 8/12/2019

Stocks making the biggest moves premarket: BlackRock, Cloudera, Tyson Foods & more Published Mon, Aug 12 2019 7:44 AM EDT Morning Report Check out the companies making headlines before the bell: BlackRockBlackRock bought a majority … is not known how long the plant will be closed. Novartis – The Swiss drugmaker is expecting faster approvals in China for its new drugs and plans to submit 50 new drug applications in China by …

Stocks making the biggest moves premarket: Pfizer, Mylan, BlackRock, Blackstone, Domino’s & more | CNBC | 7/29/2019

… of a 56 cent loss. The maker of the Cologuard colon cancer test also reported revenue that exceeded Street forecasts. BlackRock — The asset management firm is in talks to buy cybersecurity company Cofense , according to … off from Thomson Reuters , which still holds a 45% stake. Novartis — The drugmaker’s heart failure drug Entresto did not meet its goal in a trial testing its possible application for a new use. The drug …

MPM Capital

Vertex to buy VC-backed Semma for $950 mln | PE Hub | 9/3/2019

Vertex to buy VC-backed Semma for $950 mln September 3, 2019 By Iris Dorbian Vertex Pharmaceuticals Incorporated has agreed to acquire Cambridge, Massachusetts-based Semma Therapeutics , a biotech company focused on treating type 1 diabetes, for $950 million in cash. Semma’s backers include Eight Roads Ventures, Cowen Healthcare Investments, MPM Capital, F-Prime Capital Partners, ARCH Venture Partners, Novartis, Medtronic, JDRF T1D Fund, ORI Healthcare Fund, Wu Capital, 6 …

Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 7/1/2019

… has served as a consultant for Amphivena, Celgene, Bayer, Otsuka, Pfizer, Astellas Pharmaceuticals, Argenx, Astex Pharmaceuticals, Hoffman-La Roche, Janssen, Novartis, AbbVie, Sandoz, Eisai, Jazz Pharmaceuticals, Celltrion, Orsenix and Daiichi Sankyo. About AMV564-101 AMV564-101 is … in Series A, B and C venture financings led by MPM Capital, NanoDimension, Qiming Venture Partners and funds managed by Tekla Capital Management LLC. For more information, please visit www.amphivena.com . View source version on businesswire.com …

RBC Capital Markets

Biogen tops earnings expectations, but still has some longer-term issues to address - MarketWatch | 7/23/2019

RBC Capital Markets wrote in a note Tuesday morning. Analysts have long noted looming competition from other SMA treatments, like Novartis AG’s NVS, -0.51% recently-approved gene therapy Zolegensma and Roche Holding Ltd’s RHHBY, -0.18% investigational drug risdiplam. Management seemed to brush the concerns about Spinraza aside on a call with analysts on Tuesday. “It’s premature to make assumptions” about how those new drugs will do, Biogen Chief Executive Michel …

Novartis issues sunny Sandoz forecast in spite of weak U.S. generics market: analysts | FiercePharma | 7/20/2019

Novartis has spent much of the last year overhauling its generics division, Sandoz, by increasing its focus on hard-to-make drugs and doubling down on its use of digital technologies to improve everything from … On the surface, the Sandoz results looked “encouraging,” analysts from RBC Capital Markets said in a note to investors, but “the declines in the U.S. remain in the mid-teens with [a] turnaround not yet …

Atlas Venture

Cadent Therapeutics to Present at Upcoming Investor Conferences | Business Wire | 8/28/2019

Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Institutes for Biomedical Research and Slater Technology Fund. For more information, please visit cadenttx.com. Contacts Investors: Maeve Conneighton, [email protected] 212.600.1902 Media: David Rosen, [email protected] 212.600.1902 …

Cadent Therapeutics Appoints John McBride as Chief Financial Officer and Expands its Leadership Team | Business Wire | 8/21/2019

… regulatory affairs experience across a broad range of therapeutic areas, most recently serving as Director, Early Development Regulatory affairs at Novartis after an earlier tenure in regulatory affairs at Biogen Inc. Minnie earned her J.D … 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Institutes for Biomedical Research and Slater Technology Fund. For more information …

HCA

The U.S. May Have Had Its First Vaping-Related Death: Brainstorm Health | Fortune | 8/24/2019

… like they have the tools to achieve “zero harm.” A new study conducted by the Joint Commission Center for Transforming Healthcare finds that nearly 2 million health care professionals (or about 11% of the total … by facilitating more streamlined workflows. INDICATIONS FDA homes in on Novartis’ delay in reporting alleged data manipulation. The Food and Drug Administration (FDA) is questioning why drug giant Novartis took nearly two months to investigate …

Harvard Medical School

bluebird bio Appoints William R. Sellers, M.D. to Board of Directors | Business Wire | 9/27/2019

Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale …

bluebird bio Appoints William R. Sellers, M.D. to Board of Directors | BioSpace | 9/27/2019

Harvard Medical School. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for Biomedical Research overseeing scientists, clinicians and clinical staff on sites in Cambridge, East Hanover, Basel and Shanghai from 2005-2016. During his tenure he conceptualized and directed a collaboration with the Broad Institute on the Cancer Cell Line Encyclopedia, the development of the Novartis Primary Derived Xenograft Encyclopedia and large-scale …

Massachusetts General Hospital

Visiongain Report Claims there is Huge Potential Within the $28bn Stem Cell Technologies and Applications Market | PR Newswire | 9/30/2019

… Inc. Medtronic Mesoblast Miltenyi Biotec National Dental Pulp laboratory NeoStem Neuralstem New England Cord Blood Bank New York Blood Center Novartis NovoCell NurOwn Nuvasive Ocata Therapeutics OncoCyte Opexa Therapeutics OrLife Bio Orthofix Osiris Therapeutics Pahrump … Drug Administration Korean MFDS (Ministry of Food and Drug Safety) Massachusetts General Hospital McMaster University Musculoskeletal Transplant Foundation (MTF) New York Heart Association NHS Blood and Transplant Authority Northwestern University Novartis Research Foundation Oregon Health …

Easton toddler denied $2.1m gene therapy will now get it for free - The Boston Globe | 8/12/2019

… million medicine to treat her rare genetic disease, after all. Illinois-based AveXis, a subsidiary of the Swiss drug giant Novartis, has agreed to provide Zolgensma, an intravenous gene therapy that requires only one dose … application. But after receiving more documentation from Natalia’s neurologist at Massachusetts General Hospital after the Globe story was published, AveXis concluded the toddler did indeed have the worst form and was entitled to receive Zolgensma …

Memorial Sloan Kettering Cancer Center

Roche’s combo lymphoma treatment wins FDA’s accelerated approval | Yahoo News | 6/10/2019

Novartis AG, is also approved for patients with advanced DLBCL. Dr. Matthew Matasar, a hematologist at New York’s Memorial Sloan Kettering Cancer Center who was involved in the development of Polivy, said the drug could be an option for some patients to try before determining whether they need to move on to CAR-T treatments. He said Polivy can only be used once due to the risk of serious neurotoxicity …

A New Breast Cancer Treatment Can Extend the Lives of Younger Patients, Study Finds | Yahoo News | 6/5/2019

… breast cancer when given in addition to standard hormone therapy, a clinical trial has found. Data presented by the drugmaker Novartis this week at the annual American Society of Clinical Oncology (ASCO) Meeting showed that … Norton, MD, medical director of the Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York City, said the new findings were exciting. “My expectation is that, when faced with these data, it’ll …

Memorial Sloan Kettering

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine | PR Newswire | 10/8/2019

… for CD8+ T cell accumulation within tumors. Lead author of the study, Neeta Pandit-Taskar , MD, Nuclear Medicine Physician at Memorial Sloan Kettering Cancer Center, said: “This novel imaging agent has the potential to non … Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET CD8 ImmunoPET minibody …

Novel Cell Sorting and Separation Markets, 2030 | PR Newswire | 10/7/2019

… Lupin Mackay Memorial Hospital Massachusetts Institute of Technology Mayo Clinic Foundation MD Anderson Cancer Center MDxK Medigen Biotech MeMed Diagnostics Memorial Sloan Kettering Cancer Center Menarini Silicon Biosystems Merck Metabiota Microbix Biosystems MicroMedicine Middle East … Fund Newable Private Investing NextGem Nodality Northeastern University Northwestern University Novartis Novo Nordisk Ohio State Innovation Foundation On-chip Biotechnologies Oregon Health & Science University Organovo Ortho Clinical Diagnostics Orthohealing Center Management Osaka University Venture Capital …

Cleveland Clinic

Department of Health partners with Plug and Play to support healthcare startups | PR Newswire | 10/9/2019

Cleveland Clinic, Johnson & Johnson, AstraZeneca, Sanofi, Roche, Philips, Novartis, Boehringer Ingelheim, and University Hospitals. “ Abu Dhabi’s vision to become a globally recognized knowledge based economy emphasizes the importance of innovation as a key driver. We are extremely proud to announce our newest partnership with Department of Health Abu Dhabi to support Abu Dhabi , the UAE, and the wider region in sourcing and scaling healthcare technologies, leveraging Plug and Play’s international …

Visiongain Report Researches Growth Opportunities Within the $235bn OTC Pharmaceutical Market | PR Newswire | 10/2/2019

… Bukwang Pharm. Co., Ltd. Canagen Pharmaceuticals, Inc. Cardinal Health Carlyle Group Catalent Pharma Solutions Celesio China Resources Chr. Hansen Cialis Cleveland Clinic CoLucid Pharmaceuticals CR Pharmaceutical Crescent Pharma Curis, Inc. Daiichi Sankyo Delavau Pharmaceutical Partners … Inc. Nepstar Nexgen Pharma Inc. Next Nihon Eisai Co., Ltd. Novartis JV Olainfarm Olive Healthcare Omega Pharma Invest N.V. Ono Pharmaceutical Co., Ltd. ORJagdale Healthcare SL ORSL Pedialyte Perrigo Company PLC Pfizer Phoenix Procter & Gamble …

MD Anderson Cancer Center

Kaleido Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update | Globe Newswire | 8/1/2019

MD Anderson Cancer Center; C. Ronald Kahn, M.D., Head of the Section on Integrative Physiology and Metabolism, Past President & CEO, Joslin Diabetes Center, and Mary K. Iacocca Professor of Medicine, Harvard Medical School; Laura L. Kiessling, Ph.D., Novartis Professor of Chemistry, Massachusetts Institute of Technology; Max Nieuwdorp, M.D., Professor of Internal Medicine and endocrinologist, University of Amsterdam’s Faculty of Medicine (AMC-UvA); and Peter J. Turnbaugh, Ph.D., Associate Professor, Department …

Breast cancer treatment shows hope for younger women with advanced disease | NBC News | 6/1/2019

… more likely to be alive three and a half years after their diagnosis than women who only received hormone therapy. (Novartis, who makes ribociclib, funded the trial.) The treatment is aimed at women with an … cancer is hormone-receptor positive.” In the study, researchers at MD Anderson Cancer Center and UCLA Jonsson Comprehensive Cancer Center compared the survival of 672 patients with this type of breast cancer. The women were …

Cleveland Clinic, Cleveland OH

#ECTRIMS2019 – Ozanimod’s ‘Key Advantages’ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen | 9/18/2019

… doses of ozanimod were well-tolerated. One of the leading researchers in these studies, Jeffrey Cohen , MD, a neurologist at Cleveland Clinic ‘s Mellen Center for MS , shared his thoughts with Multiple Sclerosis News Today … Gilenya (fingolimod) and Mayzent (siponimod), two approved oral treatments by Novartis . S1P receptors are a type of protein found on the surface of lymphocytes (immune cells such as T- and B-cells), which are required …

A new drug could save a 1-year-old from a life of paralysis. His insurance won’t pay. | 8/8/2019

… SMA type 2 can range from early childhood to adulthood, depending on the severity of the patient’s condition, according to Cleveland Clinic. About 1 in every 11,000 children are diagnosed with SMA. It had been … him.” The drug, the companies On Wednesday, the FDA announced Novartis admitted to data manipulation during initial product testing for Zolgensma, which it reported after the gene therapy was approved. The company claimed the investigation …

Brigham and Women's Hospital

Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) | Globe Newswire | 7/29/2019

29 juil. 2019 01h01 HE Source : Novartis International AG PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will be presented … Solomon, M.D., Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, and PARAGON-HF Executive Committee Co-Chair. “The totality of evidence from the trial suggests that treatment with sacubitril/valsartan may …

Mayo Clinic

Novel Cell Sorting and Separation Markets, 2030 | PR Newswire | 10/7/2019

… Biotech Life Technologies Livzon Pharmaceuticals London Business Angels LPATH LumaCyte Luminex LungLifeAI Lupin Mackay Memorial Hospital Massachusetts Institute of Technology Mayo Clinic Foundation MD Anderson Cancer Center MDxK Medigen Biotech MeMed Diagnostics Memorial Sloan Kettering … Fund Newable Private Investing NextGem Nodality Northeastern University Northwestern University Novartis Novo Nordisk Ohio State Innovation Foundation On-chip Biotechnologies Oregon Health & Science University Organovo Ortho Clinical Diagnostics Orthohealing Center Management Osaka University Venture Capital …

Visiongain Report Claims there is Huge Potential Within the $28bn Stem Cell Technologies and Applications Market | PR Newswire | 9/30/2019

Mayo Clinic MedCell Bioscience MEDIPOST Medistem Panama Medistem Panama Inc. Medtronic Mesoblast Miltenyi Biotec National Dental Pulp laboratory NeoStem Neuralstem New England Cord Blood Bank New York Blood Center Novartis NovoCell NurOwn Nuvasive Ocata Therapeutics OncoCyte Opexa Therapeutics OrLife Bio Orthofix Osiris Therapeutics Pahrump Valley Times Pfizer Pharmicell Pharmsynthez Plasticell Pluristem Therapeutics Polyphor Precious Cell Group Prix Galien PsychENCODE Pulp Laboratory Q Therapeutics Quest Biomedical ReCyte Therapeutics Ree Labs Regenerative …

Cigna

Global Nicotine Patch Market Analysis, Growth, Size, Share, Study, Demand & Forecast 2019-2026: GSK, McNeil, Novartis, Cigna, Revolymer, Yesmoke, Habitrol | 9/27/2019

Global Nicotine Patch Market Analysis, Growth, Size, Share, Study, Demand & Forecast 2019-2026: GSK, McNeil, Novartis, Cigna, Revolymer, Yesmoke, Habitrol 3 mins ago Ann.Castro Global “ Nicotine Patch Market “ research report has all the necessary vital details asked by the clients or any audiences in terms of market advantages or disadvantages and future market scope all mentioned in a very crystal clear manner. The report eloquently mentioned all the information regarding market …

DiversityInc Hosts Conference to Address Challenges Women of Color Face in Corporate America | PR Newswire | 9/19/2019

Cigna, Cox Communications, Dow, EY, Hilton, Humana, Johnson & Johnson, Kaiser Permanente, Kellogg’s, KPMG, Marriott International, Mastercard, Nielsen, Novartis Pharmaceuticals Corporation, Sanofi, Southern Company, TD Bank, TIAA, Toyota Motor North America, and Wells Fargo. ABOUT DIVERSITYINC DiversityInc’s mission is to bring education and clarity to the business benefits of diversity. DiversityInc is the dominant “diversity” publication and publishes two websites: DiversityInc.com and the by-subscription management website, DiversityInc Best Practices. DiversityInc’s …

Aetna

Aetna joins UnitedHealth in reversing denial of $2.1M drug | Becker’s Hospital Review | 7/30/2019

Aetna reversed its coverage policy for a one-time treatment of spinal muscular atrophy weeks after UnitedHealthcare made a similar move, according to Business Insider . Under Aetna’s previous policy, the health insurer covered Novartis’ drug Zolgensma, a $2.1 million, one-time treatment for spinal muscular atrophy, only for children younger than 9 months old. The new policy will include coverage for children up to 2 years old. The FDA approved …

Aetna will now pay for more kids with a devastating rare disease to get a $2.1 million drug, reversing earlier denials | Business Insider | 7/30/2019

Health insurer Aetna will now cover a new, $2.1 million treatments for more kids living with a devastating rare disease. Under the policy change, 11-month-old Isaac Olthoff will now be able to get … been reversed.” Zolgensma, which is made by Swiss drug giant Novartis, is a new type of cutting-edge, one-time “gene therapy” treatment that treats the disease at the genetic level. The fight over Zolgensma …

Anthem

CB Stock Price - Chubb Ltd. Stock Quote (U.S.- NYSE) | MarketWatch | 5/23/2019

Novartis AG, Cigna Corp, Sells Fox Corp, Anthem Inc, Johnson & Johnson May. 9, 2019 at 1:38 p.m. ET on GuruFocus.com Everest Re Group, Ltd. Appoints Meryl Hartzband to the Board of Directors May. 23, 2019 at 2:29 p.m. ET on BusinessWire - BZX Business Travel Accident Insurance Market Analysis and Forecast From 2019 - 2024: Assicurazioni Generali, MetLife, Nationwide Mutual Insurance, Zurich, AWP Australia, AXA, American International, Chubb, Tokio Marine Holdings May …

AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect - MarketWatch | 4/24/2019

Health-care earnings announcements are in full swing. Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc. , Biogen Inc. , Boston Scientific Corp. and Swiss drugmaker Novartis AG reported on Wednesday. Next up are AbbVie Inc. ABBV, +0.85% and Bristol-Myers Squibb Co. BMY, +2.29% Here’s what investors can expect on Thursday as these two pharmaceutical giants report first-quarter earnings. AbbVie, which is expected to report earnings …

UnitedHealthcare

Another hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds | FiercePharma | 8/16/2019

UnitedHealthcare flagged as preferred was a Neupogen copy from Novartis’ Sandoz unit, which now is required for use prior to Amgen’s original biologic, follow-up treatment Granix or Pfizer’s biosim Nivestym. RELATED: Roche’s patent cliff just got steeper as FDA approves Celltrion’s Rituxan biosimilar Truxima With Herceptin and Rituxan in danger, Roche is also steeling itself for biosim competitors to its bestselling Rituxan, which hit $4.24 billion in U.S. sales …

Harvard Pilgrim Health Care

Boston drug-pricing watchdog group has pharma companies’ attention - The Boston Globe | 6/19/2019

… some of the world’s biggest drug makers charge for their products. Just last month, the head of Swiss drug giant Novartis said he could justify a price tag of up to $5 million for a … said Michael Sherman, a physician and chief medical officer for Harvard Pilgrim Health Care, the second-largest private insurer in Massachusetts. “As we come to the realization that we don’t have an unlimited global budget …

The gene therapy era has arrived. So have the challenges. | 6/7/2019

Harvard Pilgrim Health Care, in an interview with BioPharma Dive on the sidelines of the 2019 BIO conference in Philadelphia. A similar logic applies to Spark Therapeutics’ Luxturna, a gene therapy approved in the U.S. in December 2017 to treat a rare form of blindness. Novartis’ Zolgensma and Spark’s Luxturna are just the first in what’s expected to be a wave of experimental gene therapies to make it to market …

Humana

DiversityInc Hosts Conference to Address Challenges Women of Color Face in Corporate America | PR Newswire | 9/19/2019

Humana, Johnson & Johnson, Kaiser Permanente, Kellogg’s, KPMG, Marriott International, Mastercard, Nielsen, Novartis Pharmaceuticals Corporation, Sanofi, Southern Company, TD Bank, TIAA, Toyota Motor North America, and Wells Fargo. ABOUT DIVERSITYINC DiversityInc’s mission is to bring education and clarity to the business benefits of diversity. DiversityInc is the dominant “diversity” publication and publishes two websites: DiversityInc.com and the by-subscription management website, DiversityInc Best Practices. DiversityInc’s business model extracts valuable data from …

Humana Sues Drugmaker Mallinckrodt Over Alleged Price Gouging | MedCity News | 8/13/2019

Humana alleges that Mallinckrodt illegally jacked up the price of the injected drug Acthar, causing the insurance company to pay several times more for the drug - which the FDA approved in 1952 - than it otherwise … in three ways. First, it acquired rights to a competing Novartis drug not approved in the U.S., Synacthen Depot, and then shelved it without developing it for the U.S. market. Second, it artificially increased demand …

Clover Health

Top CEOs at Goldman Sachs, Salesforce, Novartis talk strategy - Business Insider | 7/19/2019

… they’re worried about, and how they lead. From Goldman Sachs CEO David Solomon to Salesforce co-CEO Keith Block, and Novartis chief Vas Narasimhan to Hulu chief Randy Freer, read on to know what your … to Vivek Garipalli , the CEO and founder of health insurer Clover Health , which set out to upend healthcare for aging Americans. He explained why, five years and $925 million in funding later, it’s proving more …

WHAT YOUR BOSS IS THINKING: We talk to the top CEOs in the world about their strategy | Markets Insider | Business Insider | 7/19/2019

… they’re worried about, and how they lead. From Goldman Sachs CEO David Solomon to Salesforce co-CEO Keith Block, and Novartis chief Vas Narasimhan to Hulu chief Randy Freer, read on to know what your … to Vivek Garipalli , the CEO and founder of health insurer Clover Health , which set out to upend healthcare for aging Americans. He explained why, five years and $925 million in funding later, it’s proving more …

Health Net

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial | Nature | 7/15/2019

Article” Ethics declarations Competing interests CFI-400945 is a proprietary compound developed at the Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre/University Health Network, with which Z.W.V., D.W.C., S.-W.L., T.D., G.F., R.B., P.S., T.J.P., J.B., M.R.B., T.W.M., and P.L.B. are affiliated. D.W.C. has provided a consulting or advisory role for Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Merck, Roche/Genentech, Agendia, and Puma Biotechnology. He has also received …

Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts | FiercePharma | 7/3/2019

Only about one-third of the top 30 U.S. insurance companies have made their decisions about how to cover Novartis’ new $2.1 million gene therapy to treat spinal muscular atrophy (SMA), Zolgensma, but analysts at … nine of the companies won’t allow concurrent treatment with Spinraza. Health Net is requiring any patient who’d used Spinraza to prove their disease progressed while on treatment before it will cover Zolgensma. Four of the …

Centene Corp

AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect - MarketWatch | 4/24/2019

Health-care earnings announcements are in full swing. Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc. , Biogen Inc. , Boston Scientific Corp. and Swiss drugmaker Novartis AG reported on Wednesday. Next up are AbbVie Inc. ABBV, +0.85% and Bristol-Myers Squibb Co. BMY, +2.29% Here’s what investors can expect on Thursday as these two pharmaceutical giants report first-quarter earnings. AbbVie, which is expected to report earnings …

SelectHealth

Novartis pitches discounts on pricey gene therapy for deadly muscle disorder - Nasdaq.com | 5/13/2019

Reuters By Deena Beasley and John Miller LOS ANGELES/ZURICH, May 10 (Reuters) - Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a … cost of therapy an important factor for them. Small insurer SelectHealth covers nearly 1 million people in Idaho and in Utah, where statewide newborn SMA testing began in 2018. SelectHealth said it has also pushed …

Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder | Yahoo News | 5/11/2019

By Deena Beasley and John Miller LOS ANGELES/ZURICH (Reuters) - Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could … cost of therapy an important factor for them. Small insurer SelectHealth covers nearly 1 million people in Idaho and in Utah, where statewide newborn SMA testing began in 2018. SelectHealth said it has also pushed …

Vas Narasimhan

Novartis, Microsoft Join Forces to Develop Drugs Using AI | 10/8/2019

Novartis and Microsoft have agreed to a five-year partnership to use artificial intelligence (AI) to develop new drugs faster, and with greater precision. Novartis CEO Vas Narasimhan said AI’s potential for personalized medicine is particularly promising, as it will help classify subgroups of patients that new drugs will most likely benefit, using clinical and preclinical datasets. Narasimhan added that these datasets were consolidated from Novartis’ internal information, surmounting integration …

GSMA Reveals First Details For MWC Barcelona 2020 | The Wapakoneta Daily News | 10/3/2019

Vas Narasimhan, CEO, Novartis Kazuhiro Yoshizawa, President and CEO, NTT Docomo Stéphane Richard, Chairman and CEO, Orange SA, Chairman GSMA Dr. Sara Spangelo, Co-Founder and CEO, Swarm CP Gurnani, CEO and Managing Director, Tech Mahindra José María Álvarez-Pallete López, Chairman and CEO, Telefónica S.A. Robert Bakish, President and CEO, Viacom For more information on the conference, visit www.mwcbarcelona.com/conference-programmes/ . More Than 2,400 Leading Companies to Participate at …

Paul Hudson

CEO Paul Hudson’s turning ‘clear eyes’ on Sanofi—and hinting at changes ahead | FiercePharma | 10/1/2019

PARIS—Sanofi’s newly installed CEO Paul Hudson asked journalists to turn an objective eye on the company—and, presumably, him—as he tunes up strategy, sets priorities and generally figures out what the French drugmaker ought to do next. He’s demanding the same from himself—and that, he freely acknowledged at a Sanofi headquarters event Tuesday, could lead to some big changes. Hudson, who joined Sanofi from Novartis early last …

Sanofi’s story needs to be ‘better told,’ new CEO says | 10/1/2019

Sanofi’s story needs to be ‘better told,’ new CEO says Sanofi share Sanofi CEO Paul Hudson, newly on the job after taking over from Olivier Brandicourt last month, is still acquainting himself with the French drugmaker. But the former Novartis executive emphasized to reporters Tuesday he views his job as helping the company be better at picking its drug development shots. “It’s clear when I talk to people inside and …

Olivier Brandicourt

Sanofi’s story needs to be ‘better told,’ new CEO says | 10/1/2019

Sanofi’s story needs to be ‘better told,’ new CEO says Sanofi share Sanofi CEO Paul Hudson, newly on the job after taking over from Olivier Brandicourt last month, is still acquainting himself with the French drugmaker. But the former Novartis executive emphasized to reporters Tuesday he views his job as helping the company be better at picking its drug development shots. “It’s clear when I talk to people inside and …

Chutes & Ladders—GlaxoSmithKline poaches Merck KGaA exec to run U.S. pharma | FierceBiotech | 8/16/2019

… president of Merck KGaA’s global oncology business and as a regional president of Pfizer’s oncology portfolio in North America. FiercePharma Novartis names Bulto new U.S. pharma chief as exec reshuffle continues Novartis Victor Bulto has … Hudson left to take the helm at Sanofi from retiring Olivier Brandicourt . FiercePharma Allergan CEO Saunders lines up for $39M parachute after AbbVie buy Allergan CEO Brent Saunders eligible for $39 million severance after takeover …

Donald Trump

Swiss Market Ends Notably Lower As Trade Tensions Escalate | Markets Insider | Business Insider | 8/23/2019

… to 1.1%, while ABB, Swatch Group and UBS Group lost nearly 1% each. Zurich Insurance, SGS, Swisscom, Swiss Re and Novartis also ended weak. In the midcap space, AMS declined nearly 4%. VAT Group ended … autos and auto parts will also be increased. U.S. President Donald Trump claimed the U.S. does not need China and would be “far better off without them” and subsequently ordered American companies to “immediately start …

Novartis consolidates $600 million media account with custom group created by Publicis’ Starcom and Epsilon | FiercePharma | 8/17/2019

And the winner is Publicis Groupe. Novartis has selected the agency to handle its global media account under a newly created group, NovartisONE2. The agency within an agency will combine the capabilities of Novartis incumbent … revelation of the $1.2 million contract Novartis inked with President Donald Trump’s once-lawyer Michael Cohen. Narasimhan has named rehabbing Novartis’ reputation as one of his top goals as CEO. While the media side of …

John Miller

Novartis to answer U.S. Senate demand for data manipulation details | Yahoo News | 8/19/2019

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen in Stein More ZURICH (Reuters) - Novartis NOVN.S plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny … has terminated several scientists amid an internal investigation. (Reporting by John Miller

Novartis heart drug fails trial, curbing growth prospects - Nasdaq.com | 7/29/2019

Reuters By John Revill and John Miller ZURICH, July 29 (Reuters) - Novartis’s heart failure drug Entresto failed a trial in a new use, the Swiss drugmaker said on Monday, calling into question billions of dollars in potential revenue and taking the shine off one of the company’s biggest growth prospects. The drug, already approved for reduced fraction heart failure, “narrowly missed” its objectives when tested on patients with preserved ejection …

Brian Kaspar

Novartis earlier acknowledged Zolgensma data errors to FDA but blamed them on poor reporting | FiercePharma | 8/27/2019

In an inspection of the Illinois manufacturing facility for Novartis’ Zolgensma earlier this year, a team of top FDA officials met with AveXis staff. Although the assay that is now at the center of Novartis … D, and his brother Brian, who was chief medical officer. Brian Kaspar insists he has done nothing wrong and hired a high-powered attorney to defend his position. The FDA investigation continues. In addition, Sen …

Chutes & Ladders—Garraway will take over as Roche’s next CMO | FierceBiotech | 8/23/2019

Novartis data scandal, taps Musk lawyer AveXis Ousted CSO Brian Kaspar has denied wrongdoing in a data manipulation scandal. Kaspar “categorically denies any wrongdoing” in a data manipulation scandal involving Novartis’ controversial gene therapy Zolgensma, according to a statement said to be from law firm Heuston Hannigan. “He is prepared to assert his rights and defend his conduct accordingly,” it added. Kaspar and his brother, Allan Kaspar , were previously leading …

Michael Cohen

Novartis Manipulated Data For Its $2.1 Million Gene Therapy. Now Patients And Biopharma Will Suffer. | Forbes | 8/20/2019

Novartis CEO had a rocky start to his tenure. Last year, the newly appointed boss was in a car when he learned that his predecessor had signed a $1.2 million contract with then Trump attorney and fixe r, Michael Cohen, for him to provide access to the Trump administration. As he told STAT’s Matt Herper: “I was not mentally prepared, nor prepared from a crisis-management standpoint. It’s not a …

Ned Sharpless

Sanders, Warren join team of senators blasting Novartis’ Zolgensma data rig | FiercePharma | 8/13/2019

… pharma company in particular. In a letter to the FDA, five Democrats, led by Sen. Richard Durbin of Illinois, blasted Novartis and its AveXis unit for submitting—and failing to quickly disclose—manipulated data that … wrote in a letter (PDF) addressed to FDA’s acting commissioner, Ned Sharpless. “Anything short of a forceful response would signal a green light to future pharmaceutical misbehavior.” The FDA last week revealed that Novartis had …

Senate panel launches probe into Novartis’ ‘reprehensible’ response to Zolgensma data irregularities | FiercePharma | 8/13/2019

Novartis caught plenty of flack with last week’s revelation that its FDA application for gene therapy Zolgensma contained manipulated data and that the company didn’t inform regulators until after its approval. Now it’s facing a … Last week, the regulator went public, and acting FDA chief Ned Sharpless said the agency is considering criminal or civil punishments. The drugmaker and regulators determined Zolgensma is safe and effective and should remain on …

Chuck Grassley

Novartis earlier acknowledged Zolgensma data errors to FDA but blamed them on poor reporting | FiercePharma | 8/27/2019

In an inspection of the Illinois manufacturing facility for Novartis’ Zolgensma earlier this year, a team of top FDA officials met with AveXis staff. Although the assay that is now at the center of Novartis … defend his position. The FDA investigation continues. In addition, Sen. Chuck Grassley, chair of the Senate Finance Committee, has launched his own and requested all records related to the incident. Also, a group of senators …

John Tsai

Novartis’ Entresto flops crucial heart failure trial, imperiling $5B sales goal | FiercePharma | 7/29/2019

by Kyle Blankenship Jul 29, 2019 10:56am After a trial flop in treating certain heart failure patients, Novartis’ Entresto is unlikely to reach its lofty $5 billion aspirations. (Novartis) Cardiovascular med Entresto’s blockbuster turn in … million people, Novartis said. SUBSCRIBE NOW Novartis R&D chief John Tsai said in a release the drugmaker would present the findings from the phase 3 trial, dubbed Paragon-HF, at the European Society of …